Abivax Is A Clinical Stage Biotechnology Company Based In Parisfrancefounded In 2013The Company Focuses On Developing Innovative Treatments That Utilize The Body S Natural Regulatory Mechanismsparticularly Through The Enhanced Expression Of Microrna 124This Approach Aims To Stabilize The Immune Response In Patients With Chronic Inflammatory Diseasesviral Infectionsand Cancer Abivax S Lead Drug Candidate Is Obefazimodoriginally Known As Abx464 Which Is Currently In Clinical Trials For Treating Ulcerative Colitisthe Company Has Successfully Completed Phase 2 Clinical Trials For This Compoundabivax Collaborates With Leading Pharmaceutical Companies And Research Institutions To Accelerate The Development Of Its Therapiesand It Has A Global Presence With Offices In Europethe United Statesand Asia
